Core Viewpoint - Sunflower (300111) is attempting another cross-industry acquisition by planning to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [1][2] Group 1: Acquisition Details - The acquisition will be executed through the issuance of shares and/or cash payments, along with a plan to raise supporting funds [1] - Following the announcement, Sunflower's stock was suspended from trading to ensure fair information disclosure and protect investor interests [1] - Prior to the announcement, Sunflower's stock price surged by 11.96% on September 5, closing at 4.96 yuan per share, with a trading volume of 6.03 billion yuan and a turnover rate of 9.93% [1] Group 2: Business Focus - Sunflower's main business focuses on the pharmaceutical sector, including the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [2] - The acquisition of Xipu Materials represents a cross-industry move, which may involve higher integration risks due to the significant difference in business operations [2] Group 3: Previous Attempts and Financial Performance - Sunflower previously attempted a cross-industry investment in March 2024, which ultimately failed due to the lack of technical progress from the partner [3] - The company reported a decline in both revenue and net profit for the first half of the year, with revenue of approximately 144 million yuan, down 8.33%, and a net profit of approximately 1.16 million yuan, down 35.68% [3]